Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TXA127 in Non-Ambulant DMD Cardiomyopathy
NCT06013839Phase 2Recruiting
- Sponsor
- Constant Therapeutics LLC
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of talfirastide in Duchenne muscular dystrophy (DMD), sponsored by Constant Therapeutics LLC. Started Aug 2023; status: recruiting.
02
Drugs
talfirastide
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06013839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06013839.